

HAWAII EMPLOYER-UNION HEALTH BENEFITS TRUST FUND
Minutes of the Benefits Committee Meeting
Thursday, April 16, 2026

TRUSTEES PRESENT

Mr. Osa Tui, Chairperson	Mr. Aedward Los Banos (via video conference)
Mr. Robert Yu, Vice Chairperson	Ms. Kristen Sakamoto
Ms. Jacqueline Ferguson-Miyamoto	Ms. Maureen Wakuzawa
Mr. Christian Fern	Mr. James Wataru
Mr. Brian Furuto	

TRUSTEES ABSENT

Ms. Sabrina Nasir

ATTORNEY

Mr. Michael Chambrella, Deputy Attorney General

EUTF STAFF

Ms. Donna Tonaki, Assistant Administrator	Ms. Lara Nitta
Ms. Desiree Yamauchi	

CONSULTANTS (Segal Consulting) (in person, unless otherwise noted)

Mr. Tyler Brotz (via video conference)	Mr. Quentin Gunn
Ms. Shelley Chun	Ms. Tammy Halter
Ms. Mary Fedor (via video conference)	Mr. Stephen Murphy (via video conference)

OTHERS PRESENT (via video conference or teleconference, unless otherwise noted)

Mr. Blaise Aquino, HMSA	Mr. Kenneth Lee, Kaiser
Ms. Sandra Benevides, CVS (in person)	Ms. Denise Mercil, Securian
Mr. Ty Bowers, CVS (in person)	Mr. Kurt Neuenfed, CVS (in person)
Mr. Francis Cuenca, CVS	Mr. Ezra Ng, HMSA
Mr. Thomas England, Kaiser	Ms. Kelsi Quon, HMSA
Ms. Sami Furutani, CVS	Ms. Taylor Relich, CVS
Mr. Galen Haneda, HMSA	Ms. Michelle Sasaki, HMSA
Mr. Gabe Hellinger, Humana	Mr. Troy Tomita, Kaiser
Ms. Meagan Kini-Ho, HMSA	Ms. Valerie Wang, Kaiser
Ms. Joey Lee, HDS	

I. CALL TO ORDER

The meeting of the Benefits Committee of the Hawaii Employer-Union Health Benefits Trust Fund (EUTF) was called to order at 9:00 a.m. by Trustee Osa Tui, Chairperson, in the EUTF Board Room, 201 Merchant Street, Suite 1700, Honolulu, Hawaii, on Thursday, April 16, 2026.

II. REVIEW OF MINUTES – March 31, 2026

The Benefits Committee reviewed the draft minutes of March 31, 2026. Since there were no edits or objections by the Trustees, the minutes stand approved.

III. NEW BUSINESS

A. CVS/SilverScript Semi-Annual Utilization Reports for the period ending December 31, 2025

Mr. Ty Bowers and Ms. Taylor Relich of SilverScript presented the plan year-end report

for the EUTF Medicare retiree prescription drug plan (EGWP) noting a claims PMPM trend of 10.3% and -3.3% after subsidies and rebates. Cost drivers include dermatologic, antidiabetic, and oncology drug spend.

Ms. Sandra Benevides, Mr. Kurt Neuenfeld and Mr. Alex Rutter of CVS Health presented the plan year-end report for the EUTF non-Medicare retiree prescription drug plan and the mid-year report for the EUTF active prescription drug plans noting a claims PMPM trend of 17.3% for non-Medicare retirees and 11.7% for actives noting that cost drivers include antidiabetic, anti-obesity, and dermatologic spend. The non-Medicare retiree increase is also due to the enrollment clean up in 2024 caused by the new benefits administration system implementation in 2022.

B. CVS Prescription Drug Plan Changes

Ms. Shelley Chun, Segal Consulting, presented a recommendation for prior authorization (with embedded step therapy and quantity limit) for Rhapsido, the first oral medication that treats chronic spontaneous urticaria (CSU), due to the high cost of the drug, new to market status, and maintaining consistent utilization management (UM) across CSU therapies.

MOTION was made and seconded to recommend to the Board addition of prior authorization (with embedded step therapy and quantity limit) for Rhapsido under the EUTF active and non-Medicare retiree prescription drug plans administered by CVS effective July 1, 2026, with grandfathering. (Yu/Wataru) The motion passed unanimously. (Employer Trustees-4/Employee-Beneficiary Trustees-5)

Ms. Benevides also presented CVS' retirement of UM for antiemetic and topical antifungal products as part of its UM optimization project. The removal would add cost but lessen member and prescriber burden. Because CVS will no longer offer UM for these products under the EUTF active and non-Medicare retiree plans effective July 1, 2026, no Board action is needed.

C. Segal Biennial Pharmacy Report (Part 1)

Ms. Chun, Ms. Tammy Halter, and Mr. Quentin Gunn, Segal Consulting, presented Part 1 of Segal's biennial pharmacy report. Segal presented its review of the active and retiree prescription drug plans through December 31, 2025, and gave an overview of trend observations, cost drivers, formulary, and CVS' biosimilar strategy.

IV. NEXT MEETING DATE – May 19, 2026

The next meeting agenda will include carrier utilization reports for the period ending December 31, 2025, retiree plan changes, and Segal annual retiree report.

V. ADJOURNMENT

MOTION was made and seconded to adjourn the meeting at 10:34 a.m. (Yu/Wataru) The motion passed unanimously. (Employer Trustees-4/Employee-Beneficiary Trustees-5)

APPROVED on May 19, 2026.

Documents Distributed:

HAWAII EMPLOYER-UNION HEALTH BENEFITS TRUST FUND

Benefits Committee Meeting

April 16, 2026 Minutes

Page 3

1. Draft Benefits Committee Minutes for March 31, 2026. (3 pages)
2. Memorandum to Benefits Committee from Program Specialist, regarding 4/16/26 Benefits Committee Meeting – Reference Sheet – Confidential, dated April 16, 2026, Redacted Version. (3 pages)
3. RxInsights, EUTF-Actives, Jan 2025 – Dec 2025, Prescription Drug Benefit Review, prepared by CVS Health, Redacted Version. (15 pages)
4. RxInsights, EUTF Non-Medicare Retiree Report, January – December 2025, Prescription Benefit Review, prepared by CVS Health, Redacted Version. (24 pages)
5. RxInsights, EUTF Medicare Retirees, Jan 2025 – Dec 2025, Prescription Benefit Review, prepared by CVS Health, Redacted Version. (26 pages)
6. Memorandum to EUTF Benefits Committee from Segal Consulting, regarding Recommendation to Implement Prior Authorization for Rhapsido (remibrutinib), dated April 16, 2026, Redacted Version. (2 pages)
7. Memorandum to Benefits Committee EUTF from CVS Health, regarding CVS Caremark Utilization Management Programs Retiring, dated April 16, 2026, Redacted Version. (1 page)
8. EUTF, Biennial Pharmacy Report, prepared by Segal Consulting, dated April 2026, Redacted Version. (31 pages)